Literature DB >> 20607257

Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure.

Mehdi Ouaissi1, Catherine Hubert, Robert Verhelst, Parla Astarci, Christine Sempoux, Anne Jouret-Mourin, Anderson Loundou, Jean-François Gigot.   

Abstract

OBJECTIVE: Combined vascular and pancreatic resection improves long-term survival of patients suffering from ductal adenocarcinoma of the pancreatic head. This study was designed to compare the results of surgical resection in patients with pancreatic cancer with or without vascular resection. Late 10-year disease-free survival was considered as an indicator of patients' disease cure.
METHODS: A total of 149 consecutive patients have undergone pancreatoduodenectomy without vascular resection (group 1: 82 patients), with isolated venous resection (group B: 67 patients), or with arterial and/or venous resection (group C: 8 patients).
RESULTS: The duration of surgery and blood losses were significantly more important in groups B and C compared with group A; however, postoperative morbidity and mortality rates were similar. R1 resection was significantly more frequent in groups B (42%) and C (50%) compared with group A (13%; p = 0.0002), but there were more advanced tumors in these groups, as demonstrated by a lower Karnowsky index, higher Ca 19-9 plasmatic level, greater tumor size, more advanced stage in the AJCC classification, and more tumor location in the uncinate process of the pancreas. Ten-year overall and disease-free survivals were significantly better in group A (19 and 20%) compared with group B (2.8 and 0%) and group C (0% and 0%). Multivariate analysis proved vascular resection and metastatic nodal status as being independent predictive factors of disease-free survival.
CONCLUSIONS: Vascular resection combined to pancreatoduodenectomy for pancreatic cancer increases local resectability without increasing mortality and morbidity rates but does not improve patients' disease cure rate.

Entities:  

Mesh:

Year:  2010        PMID: 20607257     DOI: 10.1007/s00268-010-0699-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  64 in total

Review 1.  Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?

Authors:  P Bachellier; H Nakano; P D Oussoultzoglou; J C Weber; K Boudjema; P D Wolf; D Jaeck
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

Authors:  Asma Sultana; Catrin Tudur Smith; David Cunningham; Naureen Starling; John P Neoptolemos; Paula Ghaneh
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

4.  Redefining the R1 resection in pancreatic cancer.

Authors:  C S Verbeke; D Leitch; K V Menon; M J McMahon; P J Guillou; A Anthoney
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

5.  Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.

Authors:  Antonio Sa Cunha; Alexandre Rault; Christophe Laurent; Xavier Adhoute; Veronique Vendrely; Geneviève Béllannée; René Brunet; Denis Collet; Bernard Masson
Journal:  J Am Coll Surg       Date:  2005-09       Impact factor: 6.113

6.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

7.  Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection.

Authors:  Akimasa Nakao; Shin Takeda; Mitsuru Sakai; Tetsuya Kaneko; Soichiro Inoue; Hiroyuki Sugimoto; Naohito Kanazumi
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

8.  Clinical significance of portal invasion by pancreatic head carcinoma.

Authors:  A Nakao; A Harada; T Nonami; T Kaneko; S Inoue; H Takagi
Journal:  Surgery       Date:  1995-01       Impact factor: 3.982

9.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Authors:  Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

10.  Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma.

Authors:  Takanori Yoshida; Toshifumi Matsumoto; Atsushi Sasaki; Kohei Shibata; Masanori Aramaki; Seigo Kitano
Journal:  Am J Surg       Date:  2004-06       Impact factor: 2.565

View more
  20 in total

1.  Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis.

Authors:  Yanming Zhou; Zhiming Zhang; Yujian Liu; Bin Li; Donghui Xu
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

2.  An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era.

Authors:  Marc W Fromer; Jenci Hawthorne; Prejesh Philips; Michael E Egger; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  Ann Surg Oncol       Date:  2021-06-04       Impact factor: 5.344

Review 3.  Ductal pancreatic adenocarcinoma.

Authors:  Thomas Seufferlein; Marc Porzner; Volker Heinemann; Andrea Tannapfel; Martin Stuschke; Waldemar Uhl
Journal:  Dtsch Arztebl Int       Date:  2014-05-30       Impact factor: 5.594

Review 4.  Management of borderline resectable pancreatic cancer.

Authors:  Amit Mahipal; Jessica Frakes; Sarah Hoffe; Richard Kim
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

5.  Arterial resection for pancreatic cancer: a modern surgeon should change its behavior according to the new therapeutic options.

Authors:  E Vincente; Y Quijano; B Ielpo
Journal:  G Chir       Date:  2014 Jan-Feb

Review 6.  Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Authors:  Daniel Åkerberg; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

7.  Robotic versus open pancreaticoduodenectomy with vascular resection for pancreatic ductal adenocarcinoma: surgical and oncological outcomes from pilot experience.

Authors:  Jiabin Jin; Shih-Min Yin; Yuanchi Weng; Mengmin Chen; Yusheng Shi; Xiayang Ying; Georgios Gemenetzis; Kai Qin; Jun Zhang; Xiaxing Deng; Chenghong Peng; Baiyong Shen
Journal:  Langenbecks Arch Surg       Date:  2022-01-28       Impact factor: 2.895

Review 8.  Ductal adenocarcinoma of the pancreatic head: a focus on current diagnostic and surgical concepts.

Authors:  Mehdi Ouaïssi; Urs Giger; Guillaume Louis; Igor Sielezneff; Olivier Farges; Bernard Sastre
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

9.  Pancreas club international joint symposium on pancreatic cancer 2012, Kyoto: down staging chemo±radiotherapy for borderline resectable pancreatic cancer.

Authors:  Chang Moo Kang; Ho Kyoung Hwang; Woo Jung Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2013-02-28

Review 10.  Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review.

Authors:  Sven-Petter Haugvik; Knut Jørgen Labori; Bjørn Edwin; Øystein Mathisen; Ivar Prydz Gladhaug
Journal:  ScientificWorldJournal       Date:  2012-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.